For instance, miR-26b has been reported to suppress NF-κB signaling and enhance the chemosensitivity of HCC cells by inhibiting TGF-activated kinase 1 (TAK1) and TAK1-binding protein 3 (TAB3), two positive regulators mediating the activation of canonical NF-κB pathway [144]. This evidence concerns the gene TAB3 and hepatocellular carcinoma.